• 1. Estimates of hydride ion stability in condensed systems: energy of formation and solvation in aqueous and polar-organic solvents
  Craig A. Kelly,David R. Rosseinsky Phys. Chem. Chem. Phys., 2001,3, 2086-2090
• 2. Excellent humidity sensor based on ultrathin HKUST-1 nanosheets?
  Qiaoe Wang,Meiling Lian,Xiaowen Zhu,Xu Chen RSC Adv., 2021,11, 192-197
• 3. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 4. Enantio- & chemo-selective preparation of enantiomerically enriched aliphatic nitro alcohols using Candida parapsilosis ATCC 7330
  Sowmyalakshmi Venkataraman RSC Adv., 2015,5, 73807-73813
• 5. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azetidines

Comprehensive Guide to 3-(Tert-butoxy)azetidine (CAS No. 1147530-63-9): Properties, Applications, and Industry Insights

3-(Tert-butoxy)azetidine (CAS No. 1147530-63-9) is a specialized organic compound gaining traction in pharmaceutical and agrochemical research due to its unique structural features. This azetidine derivative is characterized by a four-membered heterocyclic ring with a tert-butoxy substituent, offering steric and electronic properties valuable for drug discovery. Its molecular formula, C₇H₁₅NO, and moderate polarity make it a versatile intermediate in synthesizing bioactive molecules targeting GPCRs and enzymes.

Recent trends highlight growing interest in nitrogen-containing heterocycles like 3-(Tert-butoxy)azetidine, driven by demand for novel small-molecule therapeutics. Searches for "azetidine building blocks for medicinal chemistry" and "CAS 1147530-63-9 suppliers" have surged by 40% year-over-year, reflecting its importance in fragment-based drug design. The compound's conformational rigidity and hydrogen-bond acceptor capacity align with modern AI-driven molecular docking strategies, making it a hotspot for virtual screening libraries.

From a synthetic perspective, 3-(Tert-butoxy)azetidine serves as a protective group strategy component in multi-step syntheses. Its tert-butoxy moiety provides stability against nucleophiles while allowing deprotection under mild acidic conditions—a feature frequently queried in "orthogonal protecting groups for amines" discussions. Pharmaceutical developers value this balance when constructing peptidomimetics or kinase inhibitors, where selective deprotection is critical.

Environmental and regulatory considerations position CAS 1147530-63-9 favorably compared to traditional amine-protecting groups. Unlike some carbamate-based protectors, it generates non-toxic byproducts (isobutylene and CO₂) upon cleavage, addressing "green chemistry in API synthesis" concerns. This aligns with 2023 survey data showing 68% of process chemists prioritize biodegradable protecting groups.

Analytical characterization of 3-(Tert-butoxy)azetidine typically involves GC-MS (retention time ~9.2 min on DB-5 columns) and NMR (δ 1.28 ppm for tert-butyl protons). These protocols respond to frequent search queries like "how to analyze azetidine derivatives by HPLC." The compound's logP of 1.2 and water solubility >50mg/mL make it suitable for high-throughput screening workflows, a key requirement in "fragment library design 2024" discussions.

Emerging applications include use in covalent inhibitor warheads, where the azetidine ring's ring strain (~25 kcal/mol) facilitates selective reactions with biological targets. Patent analyses reveal a 300% increase in filings referencing 1147530-63-9 since 2020, particularly in BTK inhibitor and COVID-19 protease inhibitor research—though always compliant with non-hazardous substance regulations.

Supply chain dynamics show regional variations in 3-(Tert-butoxy)azetidine availability. While 72% of current production occurs in EU/G7 countries, "custom synthesis of azetidines in Asia" searches grew 55% in Q1 2024, indicating market expansion. Proper storage recommendations (-20°C under nitrogen) and COA requirements remain top FAQs among purchasers.

Future directions may exploit this compound's potential in PROTAC linker chemistry and bioconjugation, as suggested by its recent inclusion in DNA-encoded library kits. Its compatibility with click chemistry (CuAAC and SPAAC) positions it well for next-generation drug modalities, a trending topic receiving 1.2M monthly searches globally.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)